Aplastic anemia medical therapy: Difference between revisions
(/* Specific Treatment of Aplastic Anaemia: Matched Unrelated Donor Bone Marrow Transplantation (MUD BMT): ATG and Ciclosporin {{cite journal| author=Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC et al.| title=Guidelines for...) |
(/* Specific Treatment of Aplastic Anaemia: Matched Unrelated Donor Bone Marrow Transplantation (MUD BMT): ATG and Ciclosporin {{cite journal| author=Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC et al.| title=Guidelines for...) |
||
Line 54: | Line 54: | ||
{{cquote| | {{cquote| | ||
===Matched Unrelated Donor Bone Marrow Transplantation (MUD BMT)=== | ===Matched Unrelated Donor Bone Marrow Transplantation (MUD BMT)=== | ||
* MUD BMT may be considered when a patient has a fully matched donor, is <50 years old (or 50–60 years old with good performance status), has failed at least one course of ATG and ciclosporin, and has severe aplastic anaemia. | * MUD BMT may be considered when a patient has a fully matched donor, is <50 years old (or 50–60 years old with good performance status), has failed at least one course of [[ATG]] and [[ciclosporin]], and has severe [[aplastic anaemia]]. | ||
* There is currently insufficient data on outcome for patients >60 years of age. | * There is currently insufficient data on outcome for patients >60 years of age. | ||
* The optimal conditioning regimen for MUD BMT is uncertain, but currently a fludarabine, non–irradiation-based regimen is favoured for younger patients. | * The optimal conditioning regimen for MUD BMT is uncertain, but currently a [[fludarabine]], non–irradiation-based regimen is favoured for younger patients. | ||
}} | }} | ||
Revision as of 15:37, 23 September 2012
Aplastic anemia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Aplastic anemia medical therapy On the Web |
American Roentgen Ray Society Images of Aplastic anemia medical therapy |
Risk calculators and risk factors for Aplastic anemia medical therapy |
Editor-In-Chief: Aric Hall, M.D., Beth Israel Deaconess Medical Center, Boston, MA [1]
Overview
Medical therapy of aplastic anemia often includes a short course of anti-thymocyte globulin (ATG or anti-lymphocyte globulin) and several months of treatment with cyclosporin to modulate the immune system. Mild chemotherapy with agents such as cyclophosphamide and vincristine may also be effective. Antibodies therapy, such as ATG, targets T-cells, which are believed to attack the bone marrow. Steroids are generally ineffective.
Medical Therapy
Supportive Care in treatment of aplastic anemia [1] (DONOT EDIT)
“ |
Supportive Care
|
” |
Specific Treatment of Aplastic Anaemia: General Comments [1] (DONOT EDIT)
“ |
General Comments
|
” |
Specific Treatment of Aplastic Anaemia: Human Leucocyte Antigen (HLA)-identical Sibling Donor Transplantation [1] (DONOT EDIT)
“ |
Human Leucocyte Antigen (HLA)-identical Sibling Donor Transplantation
|
” |
Specific Treatment of Aplastic Anaemia: Immunosuppressive Therapy: ATG and Ciclosporin [1] (DONOT EDIT)
“ |
Immunosuppressive Therapy: ATG and Ciclosporin
|
” |
“ |
|
” |
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC; et al. (2009). "Guidelines for the diagnosis and management of aplastic anaemia". Br J Haematol. 147 (1): 43–70. doi:10.1111/j.1365-2141.2009.07842.x. PMID 19673883.